The two sides had initially agreed that Clover Bio would provide a first batch of 64 million doses of its recombinant protein vaccine once the product had been included in the WHO's emergency-use ...

The recombinant protein vaccine, dubbed GSK3943104, did not meet the study’s primary efficacy objective. GSK added that the vaccine candidate will not progress to phase three studies. No safety ...

The vaccine – now dubbed Vidprevtyn – is based on a recombinant protein antigen developed by Sanofi's vaccines unit Sanofi Pasteur, and also includes an immune-boosting adjuvant developed by ...

A recent WHO-led study published in Vaccine provides updated estimates on the global production capacity of influenza ...

Designed to support the development of vaccines for the 2025-2026 northern hemisphere influenza season, the new offerings include high-quality recombinant HA, NA, and NP proteins. These reagents ...

Around the world, more than a dozen intranasally delivered COVID-19 vaccines have entered clinical trials, and they run the gamut from adenovirus-vectored genes for viral antigens to recombinant ...

Vaccines Tobacco Hepatitis B virus surface ... Unfortunately, seeds containing genes for recombinant proteins can cause unintentional spread of recombinant genes or exposure of non-target ...

With a growing network of partnerships and increased funding support, we believe we are well-positioned to drive innovation, ...

Founded in 1987 in the US, Gale Smith – VP of vaccine development at Novavax – invented the technique of using insect cells for producing recombinant protein vaccines. A further milestone came ...

The Global Recombinant Chemicals Market is valued at approximately USD 2.9 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 7.8% over the forecast period 2024-2032.

These particles mimic the outer protein shell ... Lee Sherry et al, Recombinant expression systems for production of stabilised virus-like particles as next-generation polio vaccines, Nature ...